Literature DB >> 9933444

Ro/SS-A- and La/SS-B-reactive B lymphocytes in peripheral blood of patients with Sjögren's syndrome.

A Halse1, M Wahren-Herlenius, R Jonsson.   

Abstract

The aim of this study was to investigate the production of anti-Ro/SS-A and anti-La/SS-B antibodies in peripheral blood (PB) of patients with Sjögren's syndrome (SS). The ELISPOT method was performed to quantify the frequency of PB lymphocytes spontaneously secreting anti-Ro/SS-A and/or anti-La/SS-B antibodies. The total number of IgG-, IgA- and IgM-producing cells was also quantified. The recombinant Ro 52-kD, Ro 60-kD and La 48-kD proteins were used as target antigens. Three of 18 SS patients had PB lymphocytes secreting IgG antibodies against the recombinant Ro 52-kD protein. The same three patients had high serum titres of anti-Ro 52-kD antibodies. In addition, these patients were classified as having severe disease, and all three had focus scores of >/= 8 in biopsies of the labial salivary glands (LSG). The correlation between the number of PB cells producing IgG antibodies against the recombinant Ro 52-kD protein and the focus score was significant (P < 0.01). The results indicate that only SS patients with severe disease and high degree of local inflammation in LSG have B cells producing anti-Ro/SS-A antibodies in PB. Thus, most of the spontaneous autoantibody production must take place in other body compartments, e.g. in exocrine glands and probably also in the lymphoid organs and/or other mucosal sites.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9933444      PMCID: PMC1905183          DOI: 10.1046/j.1365-2249.1999.00779.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  37 in total

1.  Ro and La antigens and maternal anti-La idiotype on the surface of myocardial fibres in congenital heart block.

Authors:  A C Horsfall; P J Venables; P V Taylor; R N Maini
Journal:  J Autoimmun       Date:  1991-02       Impact factor: 7.094

2.  Sera from patients with autoimmune disease recognize conformational determinants on the 60-kd Ro/SS-A protein.

Authors:  G Boire; F J Lopez-Longo; S Lapointe; H A Ménard
Journal:  Arthritis Rheum       Date:  1991-06

Review 3.  Molecular definition of the Ro(SSA) particle(s): a frequent target of autoimmunity in systemic lupus erythematosus and Sjögren's syndrome.

Authors:  M Reichlin
Journal:  Br J Rheumatol       Date:  1991

4.  Demonstration of an amino terminal La epitope recognized by human anti-La sera.

Authors:  U Nyman; N R Ringertz; I Pettersson
Journal:  Immunol Lett       Date:  1989-07       Impact factor: 3.685

5.  Antimyelin basic protein and antimyelin antibody-producing cells in multiple sclerosis.

Authors:  T Olsson; S Baig; B Höjeberg; H Link
Journal:  Ann Neurol       Date:  1990-02       Impact factor: 10.422

6.  Identification of antigenic regions of the human Ro 60 kDa protein using recombinant antigen and synthetic peptides.

Authors:  M Wahren; U Rudén; B Andersson; N R Ringertz; I Pettersson
Journal:  J Autoimmun       Date:  1992-06       Impact factor: 7.094

7.  Autoantibodies to the Ro/SSA antigen are conformation dependent. I: Anti-60 kD antibodies are mainly directed to the native protein; anti-52 kD antibodies are mainly directed to the denatured protein.

Authors:  Y Itoh; M Reichlin
Journal:  Autoimmunity       Date:  1992       Impact factor: 2.815

Review 8.  Primary Sjögren's syndrome--clinical and laboratory markers of disease activity.

Authors:  P Oxholm
Journal:  Semin Arthritis Rheum       Date:  1992-10       Impact factor: 5.532

9.  Acetylcholine receptor-reactive T and B cells in myasthenia gravis and controls.

Authors:  H Link; O Olsson; J Sun; W Z Wang; G Andersson; H P Ekre; T Brenner; O Abramsky; T Olsson
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

10.  Function of the mammalian La protein: evidence for its action in transcription termination by RNA polymerase III.

Authors:  E Gottlieb; J A Steitz
Journal:  EMBO J       Date:  1989-03       Impact factor: 11.598

View more
  6 in total

1.  Ro/SSA and La/SSB specific IgA autoantibodies in serum of patients with Sjögren's syndrome and systemic lupus erythematosus.

Authors:  N Pourmand; M Wahren-Herlenius; I Gunnarsson; E Svenungsson; B Löfström; Y Ioannou; D A Isenberg; C G Magnusson
Journal:  Ann Rheum Dis       Date:  1999-10       Impact factor: 19.103

2.  Ro/SS-A-reactive B lymphocytes in salivary glands and peripheral blood of patients with Sjögren's syndrome.

Authors:  A Halse; J B Harley; U Kroneld; R Jonsson
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

3.  Antibody-secreting cell specificity in labial salivary glands reflects the clinical presentation and serology in patients with Sjögren's syndrome.

Authors:  Jacen S Maier-Moore; Kristi A Koelsch; Kenneth Smith; Christopher J Lessard; Lida Radfar; David Lewis; Biji T Kurien; Nina Wolska; Umesh Deshmukh; Astrid Rasmussen; Kathy L Sivils; Judith A James; A Darise Farris; R Hal Scofield
Journal:  Arthritis Rheumatol       Date:  2014-12       Impact factor: 10.995

4.  Salivary glands of primary Sjögren's syndrome patients express factors vital for plasma cell survival.

Authors:  Ewa A Szyszko; Karl A Brokstad; Gunnvor Oijordsbakken; Malin V Jonsson; Roland Jonsson; Kathrine Skarstein
Journal:  Arthritis Res Ther       Date:  2011-01-07       Impact factor: 5.156

5.  High-throughput sequencing of human plasma RNA by using thermostable group II intron reverse transcriptases.

Authors:  Yidan Qin; Jun Yao; Douglas C Wu; Ryan M Nottingham; Sabine Mohr; Scott Hunicke-Smith; Alan M Lambowitz
Journal:  RNA       Date:  2015-11-09       Impact factor: 4.942

6.  Single-cell antibody nanowells: a novel technology in detecting anti-SSA/Ro60- and anti-SSB/La autoantibody-producing cells in peripheral blood of rheumatic disease patients.

Authors:  Lida Esfandiary; Nirupama Gupta; Alexandria Voigt; Arun Wanchoo; Edward K L Chan; Sukesh Sukumaran; Cuong Q Nguyen
Journal:  Arthritis Res Ther       Date:  2016-05-17       Impact factor: 5.156

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.